Published in Kidney Int on November 01, 1996
Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant (2009) 1.70
The association of adiposity with parathyroid hormone in healthy older adults. Endocrine (2009) 1.01
Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J Clin Endocrinol Metab (2010) 0.89
Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients. Drug Des Devel Ther (2016) 0.78
Assessing the accuracy and reliability of ultrasonographic three-dimensional parathyroid volume measurement in a patient with secondary hyperparathyroidism: a comparison with the two-dimensional conventional method. Ultrasonography (2016) 0.75
Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med (1980) 4.96
A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res (1998) 4.24
beta-Lactamase proceeds via an acyl-enzyme intermediate. Interaction of the Escherichia coli RTEM enzyme with cefoxitin. Biochemistry (1980) 3.94
Weekend hospitalization and additional risk of death: an analysis of inpatient data. J R Soc Med (2012) 3.77
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med (1997) 3.48
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet (2002) 3.07
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest (2000) 2.94
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int (2008) 2.74
Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int (2008) 2.72
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology (1999) 2.69
Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone (1999) 2.69
Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res (1992) 2.65
Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology (1999) 2.65
Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology (1999) 2.27
Idiopathic osteoporosis--is the osteoblast to blame? J Clin Endocrinol Metab (1997) 2.25
Epidemiology of sarcopenia. J Am Geriatr Soc (2000) 1.97
Rickets in cation-sensing receptor-deficient mice: an unexpected skeletal phenotype. Endocrinology (2001) 1.85
Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. J Clin Endocrinol Metab (1996) 1.79
MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone (2004) 1.79
C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential. J Immunol (2001) 1.71
Assessing forearm fracture risk in postmenopausal women. Osteoporos Int (2009) 1.71
Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis (1992) 1.67
Genomic imprinting in mammals: an interplay between chromatin and DNA methylation? Trends Genet (1999) 1.67
Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions. Mayo Clin Proc (1990) 1.56
DNA methylation is linked to deacetylation of histone H3, but not H4, on the imprinted genes Snrpn and U2af1-rs1. Mol Cell Biol (2001) 1.55
Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab (2008) 1.55
Effect of gender on outcomes following renal artery stent placement for renovascular hypertension. Cathet Cardiovasc Diagn (1997) 1.43
The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology (2000) 1.43
Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med (1991) 1.42
Genetic abnormalities in sporadic parathyroid adenomas: loss of heterozygosity for chromosome 3q markers flanking the calcium receptor locus. J Clin Endocrinol Metab (1995) 1.40
Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology (2001) 1.40
Anonymity rights. Br Dent J (2010) 1.39
Rotational atherectomy for left anterior descending artery septal perforator stenosis. Catheter Cardiovasc Interv (1999) 1.39
Calcitonin: physiology and pathophysiology. N Engl J Med (1981) 1.38
Living environments and older people. Nurs Older People (2000) 1.38
Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol (1998) 1.37
Cross-sectional versus longitudinal evaluation of bone loss in men and women. Osteoporos Int (2000) 1.37
Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med (1998) 1.36
The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med (1997) 1.35
Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. Osteoporos Int (2008) 1.35
Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol (2009) 1.34
Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int (2011) 1.33
Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun (1998) 1.33
Serum ionized calcium during bed rest in fracture patients and normal men. Metabolism (1972) 1.32
Plasma calcitonin in normal man. Differences between men and women. J Clin Invest (1977) 1.28
Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology (1991) 1.28
Selective deficiency of the "bone-related" Runx2-II unexpectedly preserves osteoblast-mediated skeletogenesis. J Biol Chem (2004) 1.27
Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families. Ann Intern Med (1985) 1.27
The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int (2014) 1.27
Relationship of bone turnover to bone density and fractures. J Bone Miner Res (1997) 1.26
Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab (1996) 1.24
Persistently elevated parathyroid hormone secretion and action in young women after four weeks of ingesting high phosphorus, low calcium diets. J Clin Endocrinol Metab (1990) 1.23
The development of retinopathy in sucrose-fed and streptozotocin-diabetic rats. Diabetologia (1976) 1.22
Clinical performance of parathyroid hormone immunometric assays. Mayo Clin Proc (1992) 1.22
Relationship of intestinal calcium absorption to 1,25-dihydroxyvitamin D [1,25(OH)2D] levels in young versus elderly women: evidence for age-related intestinal resistance to 1,25(OH)2D action. J Clin Endocrinol Metab (2000) 1.22
Bone fragility in men--where are we? Osteoporos Int (2006) 1.19
Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int (2007) 1.18
Hemodialysis-associated subclavian vein stenosis. Kidney Int (1988) 1.18
Beta-lactamase inactivation by mechanism-based reagents. Philos Trans R Soc Lond B Biol Sci (1980) 1.17
Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int (1998) 1.17
Epidemiology of sarcopenia. Mayo Clin Proc (2000) 1.17
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med (2000) 1.17
Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine (2007) 1.17
Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. Metabolism (2000) 1.17
Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity. Genomics (1999) 1.17
Imprinted expression of neuronatin from modified BAC transgenes reveals regulation by distinct and distant enhancers. Dev Biol (2001) 1.16
Impaired vitamin D metabolism with aging in women. Possible role in pathogenesis of senile osteoporosis. J Clin Invest (1984) 1.15
Platelet adhesiveness and aggregation in relation to diabetic retinopathy. Diabetologia (1971) 1.15
The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol (1999) 1.13
Genomic structure and isoform expression of the mouse, rat and human Cbfa1/Osf2 transcription factor. Gene (1998) 1.12
Assessment of gene regulation by bone morphogenetic protein 2 in human marrow stromal cells using gene array technology. J Bone Miner Res (2001) 1.09
Role of the polycytin-primary cilia complex in bone development and mechanosensing. Ann N Y Acad Sci (2010) 1.07
Epidemiology of medullary carcinoma of the thyroid gland: a 5-year experience (1971-1976). Surg Clin North Am (1977) 1.06
Cbfa1 isoform overexpression upregulates osteocalcin gene expression in non-osteoblastic and pre-osteoblastic cells. J Cell Biochem (1999) 1.05
Preventing bone loss after renal transplantation with bisphosphonates: we can... but should we? Kidney Int (2000) 1.05
Elevated secretion and action of serum parathyroid hormone in young adults consuming high phosphorus, low calcium diets assembled from common foods. J Clin Endocrinol Metab (1988) 1.05
Characterization of the upstream mouse Cbfa1/Runx2 promoter. J Cell Biochem (2001) 1.05
Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res (2001) 1.04
Muscle strength in osteoporotic versus normal women. Osteoporos Int (1993) 1.04
Analysis of recombinant Phex: an endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab (2001) 1.03
Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause--a clinical research center study. J Clin Endocrinol Metab (1995) 1.02
Cloning and sequencing of human PEX from a bone cDNA library: evidence for its developmental stage-specific regulation in osteoblasts. J Bone Miner Res (1997) 1.02
Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta. J Cell Biochem (2003) 1.02
The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. J Bone Miner Res (1999) 1.02
Relative influence of physical activity, muscle mass and strength on bone density. Osteoporos Int (2000) 1.01
Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity: evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia. J Bone Miner Res (1999) 1.01
Sensing of extracellular cations in CasR-deficient osteoblasts. Evidence for a novel cation-sensing mechanism. J Biol Chem (2000) 1.01
Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem. J Clin Endocrinol Metab (2001) 1.00
Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med (1992) 1.00
Calcium infusion suggests a "set-point" abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. J Clin Endocrinol Metab (1993) 0.99
Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. J Cell Biochem (1998) 0.98
An update on the vitamin D content of fortified milk from the United States and Canada. N Engl J Med (1993) 0.98
Mutual antagonism of estrogen receptors alpha and beta and their preferred interactions with steroid receptor coactivators in human osteoblastic cell lines. J Endocrinol (2003) 0.97
Calcium homeostasis in diabetes mellitus. J Clin Endocrinol Metab (1979) 0.96
Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun (2001) 0.96
Hyperparathyroidism-jaw tumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q. Am J Hum Genet (1999) 0.96
Regulation of osteoclastogenesis and RANK expression by TGF-beta1. J Cell Biochem (2001) 0.96
Diabetes mellitus and risk of skeletal fracture. N Engl J Med (1980) 0.95